In the Spring of 2020, during the early days of the COVID-19 pandemic when there were real fears of a global downturn, PharmaVentures predicted that despite the forthcoming challenges, licensing and partnering would remain steady during 2020. With the year behind us, we are revisiting our deal closing predictions to see if they have held true.
Deal Making in the Year of Covid-19Download Request
Oxford, UK, 24th November 2020
PharmaVentures today announced it has acted as an advisor to GPCR Therapeutics, Inc (GPCR) providing due diligence for their acquisition of Burixafor targeting CXCR4.
GPCR has signed an exclusive agreement with TaiGen Biotechnology Company Ltd (TaiGen) for the development of Burixafor for worldwide markets.
GPCR Therapeutics is a leading Korean biotechnology company, a world leader in the field of GPCR heteromer science and has proprietary expertise and technology applicable to the development of this class of anti-cancer targets. CXCR4 antagonism is an accepted avenue for cancer therapy and GPCR Therapeutics has significant experience and knowledge that will enable the development of Burixafor in the oncology field.
Dongseung Seen, CEO of GPCR Therapeutics, said, “This collaboration with TaiGen, which is a leading biotech company engaged in innovative molecular-based platforms with strong R&D capabilities, will lead to a long-term strategic and productive partnership. Further, it is our goal that our work together will position us to be a pre-eminent developer of anti-CXCR4 oncology drugs.”
Summer Park, Senior Business Development Director, PharmaVentures said: “In the past decade we’ve seen more exciting innovative technologies coming out of Korea. We are proud to have supported GPCR in this process which has enabled the company to further its aim of developing novel and effective anti-cancer therapies.”
Adrian Dawkes, Managing Director at PharmaVentures, added “South Korea is forging ahead with the internationalisation of its innovative biotechnology sector and we, at PharmVentures, are pleased to be able to bring our knowledge of both Korean and Western cultures to support our Korean clients with their global transactions.”
This partnering deal follows PharmaVentures’ continued successes in working with Korean companies to enable them to expand further into the international market.
PharmaVentures is a premier transaction advisory firm; a world leader in partnering, pharma M&A deals and strategic alliances.
An unrivalled bank of specialist experience, deal analytics and network of contacts among innovators and large pharma makes PharmaVentures uniquely placed to support healthcare businesses in all aspects of deal-making and strategic planning. PharmaVentures is well known for its deep insight into deal structures and its success for generating partnering interest.
PharmaVentures Capital Ltd is a wholly owned subsidiary of PharmaVentures Ltd. All regulated activities are delivered through PharmaVentures Capital Ltd, which is authorised and regulated by the Financial Conduct Authority (741356). PharmaVentures Capital Ltd undertakes regulated activities for and on behalf of professional clients only as defined in the FCA handbook COBS 3.5.
- Pharma M&A (divestments, pharma mergers, acquisitions and strategic transactions)
- Strategy (commercialisation, deal strategy, due diligence, market entry)
- Valuation and Positioning (licensing, M&A, fundraising & expert testimonies)
- Licensing (in and out licensing)
- Expert Testimony (patent infringement, deal disagreements, taxation, determining damages)
- Private Placement Fundraising
PharmaVentures is based in Oxford, UK, employs over 20 professionals and has associates in N. America, Latin America, Asia-Pacific.
For further information, contact:
Dr Fintan Walton
+44 1865 332 700
PharmaVentures InSights: The impact of conference cancellations on dealmaking during the Covid-19 pandemic
Can Partnering Conference Cancellations Affect Dealmaking in 2020?
We all got used to the partnering conference circuit as a means to introduce the latest developments to potential partners. So now they are all temporarily suspended whilst we overcome the current global health challenge, how do you make sure your opportunities are still getting in front of your potential partners.
PharmaVentures has been successfully connecting buyers and sellers for over 28 years with and without partnering conferences. PharmaVentures’ CEO, Dr. Fintan Walton talks about how PharmaVentures is continuing a business as usual approach for all of our clients.
The last few years have seen a rise in nationalism and populism across the world. In 2016, the US voted in the populist Donald Trump on his promise to ‘Make America Great Again’. In 2018, Hungary re-elected its national conservative prime minister Viktor Orbán with the slogan ‘ For us, Hungary is first’. And in 2019, India re-elected its Hindu nationalist ruler, Nehendra Modi, and the UK elected (with a large majority) the Eurosceptic Boris Johnson on his pledge to ‘Get Brexit Done’. Other nationalist world leaders retaining their support base include Binyamin Netanyahu in Israel, and Rodrigo Duerte in the Philippines.
Is Nationalism Transforming the Pharma Manufacturing Map?Download Request
*Legitimate business purposes include contacting me regarding PharmaVentures services, commercial opportunities in M&A, Licensing, Fundraising or similar on behalf of their clients or sending me marketing material related to relevant third-party events, products and services.